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Bath University by G protein-coupled receptors, and this is the only
characterized member of the class 1B G protein-cou-Claverton Down
Bath, BA2 7AY pled PI3K family. The class IB PI3Ks are stimulated by
G protein  subunits and do not interact with the SH2-2 Novartis Horsham Research Centre
Wimblehurst Road containing adaptors that bind class IA PI3Ks. Instead,
the only identified member of this family, p110, associ-Horsham, West Sussex
United Kingdom ates with a unique p101 adaptor molecule [5]. Neverthe-
less, there is some evidence that G protein-coupled
receptors (GPCR), such as receptors for chemokines
and lysophosphatidic acid, are also able to activate theAt least one Holy Grail for many academic researchers
and pharmaceutical research divisions alike has been p85/p110 heterodimeric PI3Ks [6, 7]. In this respect, the
p85/p110 heterodimer has been demonstrated to beto identify therapeutically useful selective PI3K inhibi-
tors. There are several different but closely related synergistically activated by the subunits of G proteins
and by phosphotyrosyl peptides [8].PI3Ks which are thought to have distinct biological
roles. Until now, however, researchers have been frus- The class I PI3Ks are the most extensively studied of
these lipid kinases and can potentially generate threetrated by poor selectivity of the available pharmaco-
logical inhibitors, which are unable to distinguish the lipid products, namely phosphatidylinositol 3-mono-
phosphate [PI(3)P], phosphatidylinositol 3,4-bisphos-different isoforms of PI3K adequately. Fortunately, re-
cently published work gives cause for optimism; there phate [PI(3,4)P2], and phosphatidylinositol 3,4,5-tris-
phosphate [PI(3,4,5)P3] [4]. In vivo, the major productsare now several patent specifications published that
describe new PI3K inhibitors, including some that are of class I PI3Ks appear to be PI(3,4)P2 and PI(3,4,5)P3, as
these are transiently induced following cell stimulation.more selective for the delta isoform of PI3K. Given
the involvement of PI3Ks in a plethora of biological They can selectively bind certain pleckstrin homology
domains, modular segments of about 100 amino acidssettings, such isoform-selective inhibitors may have
immense potential use for the treatment of patients found in many signaling proteins. The ability of PH do-
mains within different proteins to discriminate PI(3,4)P2with inflammatory and autoimmune disorders as well
as cancer and cardiovascular diseases. and PI(3,4,5)P3 from each other and from other PI lipids
could be central to the specificity of PI3K signaling. It
is these PH-domain-containing proteins that are ableIntroduction
Phosphoinositide 3-kinases (PI3Ks) were first identified to propagate and drive further downstream signaling
events, and the best characterized PI3K effector mole-as an activity associated with various oncoproteins and
growth factor receptors [1, 2], and evidence soon accu- cule is protein kinase B (PKB/Akt). The PI3K family is
completed by the class II C2-domain-containing PI3Ksmulated that PI3Ks can provide a critical signal for cell
proliferation, cell survival, membrane trafficking, glu- and the class III PtdIns-specific 3-kinases [4]. The class
II PI3Ks (comprising , , and  isoforms) are character-cose transport, neurite outgrowth, membrane ruffling,
and superoxide production as well as actin reorganiza- ized by the presence of a C2 domain at the carboxyl
terminus and utilize predominantly PI and PI(4)P as sub-tion and chemotaxis [3, 4]. The diverse nature of PI3K
functional effects is reflected in its activation by multiple strates in vitro [9]. In contrast to members of the other
PI3K classes, PI3K-C2 is refractory to inhibition byreceptors, the existence of three classes and several
isoforms of PI3K, and multiple effector proteins that can the PI3K inhibitor wortmannin [9]. Recent evidence has
indicated that clathrin functions as an adaptor for classinteract with PI3K lipid products by distinct structural
motifs [3, 4]. II PI3K-C2, binding to its N-terminal region and stimu-
lating its activity [10]. The class III PI3Ks utilize only PIThe term PI3K is applied to a family of lipid kinases
that can be classified into three subfamilies according as a substrate (e.g., mammalian PI 3-kinase and yeast
Vps34p) [4]. A clearer picture is now emerging of theto structure and substrate specificity (Table 1) [4]. The
class I group of PI3Ks consists of two subgroups. The importance of individual catalytic isoforms in distinct
biological effects, which will be highlighted later in thisprototypical class IA PI3K consists of an 85 kDa regula-
tory subunit (responsible for protein-protein interactions review.
The termination of PI3K signaling by degradation ofvia SH2 domain interaction with phosphotyrosine resi-
dues of other proteins) and a catalytic 110 kDa subunit. PI(3,4,5)P3 can be mediated by at least two different
types of phosphatases, namely SH2-containing inositolThere are three catalytic isoforms (p110, p110, and
p110) and five regulatory isoforms (p85, p85 and 5-phosphatase (SHIP) [11] and the 3 phosphatase
termed phosphatase and tensin homology deleted on
chromosome ten protein (PTEN) [12, 13]. Dephosphory-*Correspondence: s.g.ward@bath.ac.uk (S.W.), peter.finan@pharma.
novartis.com (P.F) lation of PI(3,4,5)P3 by SHIP impairs some downstream
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philic attack of Lys802 of p110 results in formation ofTable 1. PI3K Family Members
an enamine (at C-20) achieving covalent modification of
Catalytic Adaptor/Binding PI3K (Figure 1) [15]. Nucleophilic residues equivalent to
Class Subunit Partner Distribution
Lys802 are present in all PI3Ks and protein kinases,
IA p110 p85, p50, p55 Broad such as myosin light chain kinase, protein kinase A, and
p110 p85 Broad DNA-dependent protein kinase catalytic subunit as well
p110 p55 Leukocytesa as TOR-related proteins, and probably account for the
IB p110 p101 Leukocytesa
poor selectivity of wortmannin.II PI3K-C2//c Clathrin Broadb
Bioflavanoid-Related CompoundsIII PtdIns 3-kinase p150 Broad
The bioflavanoid quercetin (structure 2, Figure 1) was
a p110 and p110 have been considered leukocyte specific, but
initially shown to effectively inhibit PI3K with an IC50recent work suggests that they are more broadly expressed.
of 3.8 M but has poor selectivity, inhibiting relatedb Type II C2 is the only PI3K that is substantially resistant to the
enzymes such as PI 4-kinase and several tyrosine andinhibitor wortmannin.
c PI3K-C2 is liver specific. serine/threonine kinases [16]. Using quercetin as a
model compound, several chromenones were synthe-
sized and evaluated for their ability to inhibit PI3Ks. The
placement of a phenyl moiety at the 8 position of theeffects of PI3K, although the metabolic product of SHIP
chromenone ring resulted in a potent compound,phosphatase activity is PI(3,4)P2, which can also mediate
LY294002 [17] (structure 3, Figure 1), that completelyPI3K-dependent responses.
inhibits PI3K at 100 M [17]. Both of these compounds
are competitive inhibitors at the ATP binding site ofFirst Generation PI3K Inhibitors
PI3K, but unlike quercetin, LY294002 has no detectableThe availability of PI3K inhibitors has contributed greatly
effect on other ATP-requiring enzymes such as proteinto our current understanding of the biological role of
kinases and PI 4-kinase [17]. Despite a reported IC50PI3Ks and their effector proteins. The major pharmaco-
about 500-fold higher than wortmannin, LY294002 haslogical tools that have been used in this respect are
the advantage of being more stable in solution and hasassessed below.
been widely used in cell biology, being almost as instru-Wortmannin
mental as wortmannin in characterizing the biologicalDespite limitations in selectivity, the fungal metabolite
importance of PI3K signaling pathways. Although PI3K-wortmannin isolated from Penicillium wortmanni (struc-
C2 is refractory to both inhibitors, neither wortmanninture 1, Figure 1), has proven to be an invaluable tool
nor LY294002 exhibit any degree of selectivity for indi-with which to assess the functional relevance of PI3K
vidual PI3K isoforms.activation in many settings. The concentration of wort-
mannin required to inhibit PI3Ks ranges from 1–100 nM
(reviewed in [14]). Irreversible inhibition of lipid and ser- Lessons from Structural Analysis
Most protein kinase inhibitors in development for phar-ine kinase activity of class 1 and class III PI 3-kinases
occurs by covalent modification of the catalytic sites maceutical application work by competing with ATP
binding. Despite the overall similarity of the ATP binding[15]; class II PI3Ks are also inhibited at higher concentra-
tions (e.g.,100 nM). The highly electrophilic C-20 posi- sites among protein kinases, it has been possible to
exploit local variation in the mode of ATP binding intion of the furan ring of wortmannin is thought to be
responsible for alkylation of the protein, so that nucleo- order to develop protein kinase-specific inhibitors that
Figure 1. First Generation PI3K Inhibitors
(A) Structure of wortmannin highlighting the
region responsible for nucleophilic attack of
Lys802 of PI3K. (B) Structures of the bioflava-
noid quercetin and its derivative LY294002.
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have led to promising clinical applications [18, 19]. This terization of the compounds, and the compounds are not
commercially available. Nevertheless, the compoundsapproach has proven highly successful in the develop-
ment of EGF-R inhibitors (e.g., IRESSA, developed by reported in these patents do represent promising lead
compounds for the future development of PI3K isoform-AstraZeneca) for the treatment of solid tumors and cAbl
inhibitors (e.g., Glivec, developed by Novartis) that are selective inhibitors. In this respect, Yamanouchi has de-
scribed several imidazopyridine derivatives, (e.g., com-among the vanguard of attack in treating patients with
chronic myeloid leukemia. pounds of general structure 4, Figure 2). These are
claimed to exhibit excellent PI3K inhibitory activities,Interesting insights into the possible development of
isoform-selective PI3K inhibitors have been provided by especially against p110, although no isoform selectiv-
ity data are provided [22]. Thrombogenix disclosed adetermination of the crystal structure of PI3K [20]. This
structure reveals a multidomain organization with the series of morpholino-substituted compounds closely re-
lated to LY294002 that for the first time were able to elicitcatalytic domain of PI3K having a similar fold to that of
the protein kinases. The catalytic domain has two lobes: any degree of isoform selectivity [23]. They described
quinolone and pyridopyrimidine compounds (structuresa smaller N-terminal lobe consisting of a five-stranded
 sheet flanked by three  helices and a larger primarily 5 and 6, Figure 2) that are approximately 100-fold more
potent against / isoforms compared to  isoforms,helical C-terminal lobe. The ATP cosubstrate binds be-
tween these two lobes in a manner similar to ATP binding exhibiting submicromolar activity against p110/
compared to micromolar activity against  (Table 2).in protein kinases, with many of the enzyme-ATP con-
tacts involving residues in the linker region between A recently published patent application from the ICOS
Corporation describes compounds that have high selec-the two lobes. X-ray crystallography of PI3K bound to
various PI3K inhibitors has revealed how these com- tivity for inhibition of p110 [24]. They report several
quinazolinone compounds (e.g., structures 7 and 8, Fig-pounds fit into the ATP binding pocket. Wortmannin,
LY294002, and quercetin all bind to the ATP binding site ure 2) that display selectivity for p110 versus PI3K
and p110 and , with the most potent exhibiting aroundof PI3K such that the aromatic portion of the compound
occupies the space that is normally occupied by the 40-fold greater selectivity for p110 versus the other
isoforms (Table 2). A recent publication reports thatadenine base, with a hydrogen-bond acceptor in a posi-
tion approximating to the N1 atom of PI3K-bound ATP. methylxanthines such as caffeine and theophylline
(structures 9 and 10, Figure 2) are selective for p110Wortmannin binds irreversibly to the enzyme and causes
a small distortion in the packing of the neighboring side isoforms over p110 and p110 isoforms, although their
activity is rather low [25]. To date, no PI3K-selectivechains in the catalytic domain. The close shape comple-
mentarity between the PI3K active site and wortmannin inhibitor has been reported in the literature.
together with the irreversible modification are impor-
tant determinants of the low nanomolar IC50 for this
Therapeutic Potential for PI3K Inhibitorscompound. However, neither LY294002 nor quercetin
Inflammation and Autoimmune Diseasecauses conformational changes, although remarkably,
The catalytic subunit isoforms p110 and p110 havethey bind PI3K in different orientations that are related
sparked a great deal of interest among immunologiststo each other by 180 rotations.
and pharmaceutical companies alike, because their ex-
pression is largely restricted to leukocytes, and there is
increasing evidence that these isoforms in particularIsoform Selective Inhibitors: The Next Generation
Insights into the structural determinants of PI3K inhibi- play key roles in innate and adaptive immunity. This
view has been borne out by several studies, some oftors as outlined above should provide a valuable impe-
tus for the design and development of isoform-selective which are mentioned here. A hallmark of inflammatory
responses is the migration of leukocytes to the inflam-inhibitors. However, binding properties of individual
compounds and the degree to which structural plasticity matory lesion in response to chemokines and other che-
moattractants. Several studies suggest that the polar-of the enzyme might be exploited by any therapeutic
lead compound are hard to predict. It is worth repeating ized activation of PI3K at the leading edge of a migrating
cell and subsequent PI(3,4,5)P3-dependent recruitmentthe caution noted by Cohen and coworkers that the
selectivity of protein kinase inhibitors cannot be taken of PKB and possibly other PH-domain-containing pro-
teins is a crucial and early event in the detection of afor granted by only testing against structurally related
enzymes, as inhibitors previously reported as selective chemoattractant gradient [26–29]. The phenotype of
two-knockout mice models has reinforced the view thathave often been shown to inhibit protein kinases not
closely related in primary structure to the original target. PI3K isoforms can significantly contribute to inflamma-
tory responses. First, studies of mice lacking PI3K haveFor example, wortmannin is known to potently inhibit
myosin light chain kinase, while LY294002 has been shown that this isoform is essential for PI(3,4,5)P3 pro-
duction and PKB activation as well as superoxide pro-shown to potently inhibit casein kinase-2 [21].
Recently, a number of patent specifications have been duction in neutrophils exposed to the chemoattractants
that act via GPCRs (e.g., fMLP, C5a, and IL-8). Chemo-published which describe inhibitors of PI3K, including
compounds that exhibit some selectivity for individual taxis of cells involved in mounting an inflammatory re-
sponse (e.g., neurophils, macrophages, and T lympho-p110 catalytic isoforms (Figure 2 and Table 2). It is impor-
tant to stress that the patents which describe these so- cytes) was also impaired in the absence of PI3K, both
in vitro and in vivo [30–32]. Second, SHIP	/	 mice suffercalled second generation inhibitors do not necessarily
provide detailed information as to the biological charac- from lethal infiltration of the lungs by macrophages and
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Figure 2. Second Generation PI3K Inhibitors
Structure of new PI3K inhibitors: imidazo-
pyridines (general structure 4) reported by
Yamanouchi; quinolone (structure 5) and py-
ridopyrimidine (stucture 6) described by
Thrombogenix; quinazolinone (structures 7
and 8) reported by ICOS as well as caffeine
(structure 9) and theophylline (structure 10).
neutrophils. Thus, persistently high levels of the as impaired in vivo immune responses, suggesting a
key role for p110 in immunity [34]. The selective attenu-PI(3,4,5)P3 and subsequent activation of its downstream
effectors might lead to excessive inflammation [33]. ation of immune function in these p110 mutant mice
suggests that a specific inhibitor of p110 could effec-Given that PI3K has been proposed to be the major
isoform responsible for producing PI(3,4,5)P3 in re- tively suppress B and T cell mediated autoimmunity and
possibly B and T cell transformation.sponse to chemoattractants, it seems likely that selec-
tive inhibitors of PI3K would be potentially useful in A p110 isoform-specific inhibitor would be predicted
to have similar effects as expression of a catalyticallypreventing inflammatory cell recruitment in a range of
inflammatory diseases including asthma, rheumatoid ar- dead p110mutant. Indeed, p110-specific compounds
also significantly inhibited IgM and IgG production fromthritis, multiple sclerosis, and inflammatory bowel
disease. B cells and B cell proliferation in response to IgM stimu-
lation and inhibited T cell proliferation in response toInsights into the biological role of p110 have also
been provided by an elegant study in which a new strat- CD3 and CD28 costimulation [24]. The p110-specific
compounds also provide an insight into the role of thisegy was adopted to address the role of the p110 iso-
form [34]. Instead of deletion of a particular p110 isoform isoform in a variety of other cellular functions. In neutro-
phils, for example, -specific inhibitors prevent the pro-gene which alters expression of other isoforms, knockin
mice expressing a mutated and catalytically dead p110 duction of superoxide by N-formyl-Met-Leu-Phe (fMLP)
as well as fMLP-stimulated elastase release and fMLP-were generated. This approach prevented changes in
the expression levels of the other PI3K catalytic and induced cell migration. This is rather surprising given
that the G protein  subunit-dependent p110 catalyticregulatory subunits. These mice exhibit impaired anti-
gen receptor signaling in T and B lymphocytes as well isoform has been suggested to be the sole contributor
Table 2. Relative Potency of Second Generation PI3K Inhibitors against Individual Isoforms
Inhibitor IC50 M Reference
PI3K / Selective PI3K  PI3K  PI3K  PI3K 
Quinolone (structure 5) 0.02 5 ND 23
Pyridopyrimidine (structure 6) 0.05 10 ND 23
PI3K  Selective
Caffeine 400 400 1000 75 25
Theophylline 300 800 800 75 25
Quinazolinone (structure 8) 2.0 2.0 2.0 0.05 24
IC50 values are derived from different studies in which there is likely to be variation in source of enzyme and experimental conditions. Refer
to Figure 2 for structures and source of compounds. ND, not determined.
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to lipid accumulation in response to several different There is a growing body of evidence that PI3Ks play
an important role in regulating vascular tone as wellligands that activate distinct GPCRs [31, 35]. It seems,
therefore, that p110 can also participate in GPCR sig- as myocardial contractility and cell size. Consequently,
dysfunction of PI3K-dependent signaling pathway maynaling, indicating that some redundancy of function may
exist between the two isoforms. be important in the pathogenesis and pathology of other
cardiovascular diseases such as hypertension. TheCardiovascular Disease
Platelet activation involves cytoskeletal rearrangements spontaneous tone generated in hypertensive rats was
eliminated by the PI3K inhibitors LY294002 and wort-and granule secretion and converts the fibrinogen re-
ceptor (the integrin IIb3) from low- to high-affinity mannin, whereas hypertensive rat aortas showed en-
hanced PI3K activity associated with increased expres-binding state. Platelets express p110, , and  (but not
) that are believed to play important roles in aggregation sion of the PI3K subunits, p110 and p110 [39, 40].
Thus, selective inhibitors for p110 isoforms may be use-[36]. Indeed, aggregation in response to thrombin and
phorbol ester stimulation is sensitive to wortmannin. ful in treatment of hypertension.
CancerHowever, many soluble platelet stimuli, including ADP,
thromboxane A2, and thrombin, exert their physiological Evidence for the role of PI3K in the progression of human
cancers is largely circumstantial. However, bearing inactions through GPCRs. It is interesting to note, there-
fore, that platelets lacking the G protein-activated PI3K mind that many oncogenic signaling pathways are medi-
ated by PI3K and that PTEN, the 3 phosphatase thatisoform exhibit impaired aggregation and IIb3 fibrino-
gen receptor activation as well as reduced thromboem- breaks down PI(3,4,5)P3 is a tumor suppressor, it would
seem likely that there is potential benefit from develop-bolism when modeled in vivo [37]. Thus, pharmacologi-
cal targeting of PI3K as well as p110 and  may have ing PI3K inhibitors for the treatment of cancer. Increased
PI3K activity may lead to aberrant control of the cellpotential use as antithrombotic therapy.
Some impressive advances in our understanding of cycle, increased survival from apoptosis, and promotion
of a metastatic phenotype. PI3K inhibitors may blockthe crucial role PI3K isoforms play in cardiomyocyte
contractility have recently been achieved with the use of each of these facets of tumorigenesis.
Amplification of the PIK3CA gene has been observedcardiac-specific PTEN knockout mice. Amazingly, these
mice exhibited spontaneous cardiac hypertrophy as well in several carcinomas [41, 42]. Mutation of the lipid
phosphatase PTEN is one of the most common muta-as decreased contractility when either whole hearts or
single cardiomyocytes were examined [38]. Analysis of tions in human cancer [43]. In addition, PKB amplifica-
tion and increases in PKB kinase activity have beendouble-mutant mice that were deficient in PTEN and
also expressed dominant-negative mutants of either widely reported in tumor tissue [44]. The number of PKB
substrates is also rapidly expanding, and many of thesep110 or PI3K revealed that the cardiac hypertrophy
and contractility defects could be genetically uncoupled. proteins are well-characterized modulators of cell
growth and survival. The cyclin-dependent kinaseThus, the increase in cell size found in PTEN-deficient
hearts could be reversed in mice that were deficient in p27Kip1, which normally resides in the nucleus, is located
in the cytoplasm in a variety of tumors. Recent studiesPTEN but also transgenically overexpressed a heart-
specific dominant-negative mutant of p110. Overex- have shown that p27 phosphorylation by PKB blocks
entry into the nucleus and that p27 cytosolic localizationpression of a dominant-negative p110 on a wild-type
background affects heart size but has no effect on heart correlated with poor patient survival [45–47]. Another
substrate of PKB is the oncoprotein Mdm2, phosphory-function, while the PTEN-deficient mice expressing the
p110 mutant still displayed a marked decrease in con- lation of which promotes its nuclear entry, leading to
the degradation of the tumor suppressor, p53 [48].tractility. This latter observation suggested the involve-
ment of a distinct PI3K isoform in the regulation of heart The PI3K inhibitors wortmannin and LY294002 have
been shown to block the proliferation of numerous can-contractility. Indeed, the deficits in cardiomyocyte and
whole-heart contractility from PTEN-deficient mice were cer cell lines in vitro and are effective in xenograft mod-
els [49, 50]. In addition, PI3K inhibitors have been shownreversed when a dominant-negative form of PI3K was
coexpressed in PTEN-deficient mice, whereas mice de- to enhance the effects of radiation and cytotoxic agents
[51, 52]. These effects may be partially due to the inhibi-ficient in PI3K activity alone exhibited enhanced cardi-
omyocyte and whole-heart contractility [38]. Although tion of the closely related kinases ATM and DNA-PK but
may also occur due to an enhancement of apoptosis inexpression of PI3K has been generally considered to
be leukocyte restricted, this study reported strong ex- treated cells. The prospects for PI3K inhibitors in the
treatment of cancer look promising. One advantage ofpression of PI3K protein in total heart extracts of mice
and in isolated cardiomyocytes. It transpires that PI3K such an approach would be the opportunity to interfere
with multiple signaling pathways, allowing the blockaderegulates cardiac function by negatively regulating
cAMP levels upon GPCR-coupled 2-adrenergic recep- of both tumor proliferation and angiogenesis mediated
by growth factors such as vascular endothelial growthtor stimulation [38]. In cardiomyocytes, increased cAMP
levels result in enhanced contractility via activation of factor (VEGF). The level of PI3K isoform selectivity that
is required in such inhibitors and the optimal dosingprotein kinase A and subsequent phosphorylation of
phospholamban in the sarcoplasmic reticulum. This regimen remain to be determined. Finally, chemokine
receptors have been shown to be involved in breastsuggests that downregulation of cAMP levels by PI3K-
dependent mechanisms impairs contractility and leads cancer metastasis [53]. Given that these receptors are
strongly coupled to PI3K isoforms [7], this would sug-to the exciting prospect that selective inhibition of PI3K
may induce better cardiac contractility during heart gest that PI3K inhibitors might reduce the risk of cancer
metastasis.failure.
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clathrin and regulates clathrin-mediated membrane trafficking.Conclusion
Mol. Cell 7, 443–449.Clearly, the therapeutic potential for isoform-selective
11. Rohrschneider, L.R., Fuller, J.F., Wolf, I., Liu, Y., and Lucas,PI3K inhibitors is huge. However, there are still some
D.M. (2000). Structure, function and biology of SHIP proteins.
questions about redundancy of function between PI3K Genes Dev. 14, 505–520.
isoforms, and it is perhaps worth emphasizing that even 12. Cantley, L.C., and Neel, B.G. (2000). New insights into tumour
suppression: PTEN suppresses tumour formation by restrainingisoform-selective inhibitors may present problems. For
the phosphoinositide 3-kinase/Akt pathway. Proc. Natl. Acad.example, it is worth noting that p110 mutant mice de-
Sci. USA 96, 4240–4245.veloped a mild inflammatory bowel disease, suggesting
13. Wishart, M.J., and Dixon, J.E. (2002). PTEN and myotubularinnot only that the human p110 gene may be a human
phosphatases: from 3-phosphoinositide dephosphorylation to
inflammatory bowel disease susceptibility gene, but disease. Trends Cell Biol. 12, 579–585.
also that p110 may be required for homeostatic im- 14. Ward, S.G., June, C.H., and Olive, D. (1996). PI 3-kinase: a pivotal
pathway in T cell activation. Immunol. Today 17, 187–197.mune responses to normal gut flora. In addition, chronic
15. Wymann, M.P., Bulgarelli-Leva, G., Zvelebil, M.J., Pirola, L., Van-activation of p110 and PKB using transgenic ap-
haesebroeck, B., Waterfield, M.D., and Panayotou, G. (1996).proaches reveals a spectrum of phenotypes ranging
Wortmannin inactivates phosphoinositide 3-kinase by covalentfrom no cardiomyopathic changes, moderate cardiac modification of Lys-802, a residue involved in the phosphate
hypertrophy with preserved systolic function, to massive transfer reaction. Mol. Cell. Biol. 16, 1722–1733.
cardiac dilatation and sudden death [54–56]. There is 16. Matter, W.F., Brown, R.F., and Vlahos, C.J. (1992). The inhibition
of phosphatidylinositol 3-kinase by quercetin and its analogs.strong evidence, however, that acute PKB activation
Biochem. Biophys. Res. Commun. 186, 624–631.protects cardiomyocytes from apoptosis in vitro and in
17. Vlahos, C.J., Matter, W.F., Hui, K.Y., and Brown, R.F. (1994). Avivo and dramatically reduces infarction and cardiac
specific inhibitor of phosphatidylinositol 3-kinase 2-(4-morpho-
dysfunction 24 hr after transient ischaemia [57, 58]. linyl)-8-phenyl-4H–1-benzopyran-4-one (LY294002) J. Biol.
Thus, the use of p110- and -selective inhibitors as Chem. 269, 5241–5248.
therapeutic agents may well be tempered by their poten- 18. Toledo, L.M., Lydon, N.B., and Elbaum, D. (1999). The structure-
based design of ATP-site directed protein kinase inhibitors.tial to increase susceptibility to infarct. Such issues will
Curr. Med. Chem. 6, 775–805.have to be given careful consideration, but for now, the
19. Garcia-Echeverria, C., Traxler, P., and Evans, D.B. (2000). ATPavailability of promising lead compounds should provide
site-directed competitive and irreversible inhibitors of protein
the momentum to develop new compounds with better kinases. Med. Res. Rev. 20, 28–57.
spectra of selectivity for future therapeutic use. 20. Walker, E.H., Pacold, M.E., Perisic, O., Stephens, L., Hawkins,
P.T., Wymann, M.P., and Williams, R.L. (2000). Structural deter-
minants of phosphoinositide 3-kinase inhibition by wortmannin,
References LY294002, quercetin, myricetin, and staurosporine. Mol. Cell 6,
909–919.
1. Whitman, M., Downes, C.P., Keeler, M., and Cantley, L.C. (1998). 21. Davies, S.P., Reddy, H., Caivano, M., and Cohen, P. (2000).
Type I phosphatidylinositol makes a novel inositol phospholipid, Specificity and mechanism of action of some commonly used
phosphatidylinositol-3-phosphate. Nature 332, 644–646. protein kinase inhibitors. Biochem. J. 351, 95–105.
2. Courtneidge, S.A., and Heber, A. (1987). An 81-kd protein com- 22. Hayakaa, M., Kaizawa, H., Kawaguchi, K.I., Matsuda, K., Ishi-
plexed with middle T-antigen and pp60c-src—a possible phos- kawa, N., Koizumi, T., Yamanao, M., and Ohta, M. June 2002.
phatidylinositol kinase. Cell 50, 1031–1037. Therapeutic morpholino-substituted compounds. U.S. patent
3. Cantley, L.C. (2000). The phosphoinositide 3-kinase pathway. 6,403,588 B1.
Science 296, 1655–1657. 23. Robertson, A.J., Jackson, S., Kenche, V., Yaip, C., Parbaharan,
4. Vanhaesebroeck, B., Leevers, S.J., Ahmadi, K., Timms, J., H., and Thompson, P. July 2001. Preparation and formulation of
Katso, R., Driscoll, P.C., Woscholski, R., Parker, P.J., and Wa- morpholino-substituted heterocycles as phosphoinositide
terfield, M.D. (2000). Synthesis and function of 3-phosphory- 3-kinase inhibitors for therapeutic use. International patent ap-
lated inositol lipids. Annu. Rev. Biochem. 70, 535–602. plication WO 0153266 A1.
5. Stephens, L.R., Eguinoa, A., Erdjument-Bromage, H., Lui, M., 24. Sadhu, C., Dick, K., Treiberg, J., Sowell, C.G., Kesicki, E.A., and
Cooke, F., Coadwell, J., Smrcka, A.S., Thelen, M., Cadwallader, Oliver A. November 2001. Quinazolinone derivatives as inhibi-
K., Tempst, P., and Hawkins, P.T. (1997). The G sensitivity of tors of human phosphatidylinositol 3-kinase delta. International
a PI3K is dependent upon a tightly associated adaptor, p101. patent application WO 0181346 A2.
Cell 89, 105–114. 25. Foukas, L.C., Daniele, N., Ktori, C., Andersen, K.E., Jensen, J.,
6. Yart, A., Roche, S., Wetzker, R., Laffargue, M., Tonks, N., May- and Shepherd, P. (2002). Direct effects of caffeine and theophyl-
eux, P., Chap, H., and Raynal, P. (2000). A function for phospho- line on p110delta and other phosphoinositide 3-kinases. J. Biol.
inositide 3-kinase- lipid products in coupling  to Ras activa- Chem. 277, 37124–37130.
tion in response to lysophosphatidic acid. J. Biol. Chem. 277, 26. Wang, F., Herzmark, P., Weiner, O.D., Srinivasan, S., Servant,
21167–21178. G., and Bourne, H.R. (2002). Lipid products of PI(3)Ks maintain
7. Sotsios, Y., and Ward, S.G. (2000). Phosphoinositide 3-kinase: persistent cell polarity and directed motility in neutrophils. Nat.
a key biochemical signal for cell migration in response to che- Cell Biol. 4, 513–518.
mokines. Immunol. Rev. 177, 217–235. 27. Weiner, O.D., Neilsen, P.O., Prestwich, G.D., Kirschner, M.W.,
8. Kurosu, H., Maehama, T., Okada, T., Yamamoto, T., Hoshino, S., Cantley, L.C., and Bourne, H.R. (2002). A PtdInsP(3)- and Rho
Fukui, Y., Ui, M., Hazeki, O., and Katada, T. (1996). Heterodimeric GTPase-mediated positive feedback loop regulates neutrophil
phosphoinositide 3-kinase consisting of p85 and p110 is syn- polarity. Nat. Cell Biol. 4, 509–512.
ergistically activated by the  subunits of G proteins and phos- 28. Iijima, M., and Devreotes, P. (2002). Tumor suppressor PTEN
photyrosyl peptide. J. Biol. Chem. 272, 24252–24256. mediates sensing of chemoattractant gradients. Cell 109,
9. Domin, J., Pages, F., Volinia, S., Rittenhouse, S.E., Zvelebil, M.J., 599–610.
Stein, R.C., and Waterfield, M.D. (1997). Cloning of a human 29. Funamoto, S., Meili, R., Lee, S., Parry, L., and Firtel, R.A. (2002).
phosphoinositide 3-kinase with a C2 domain that displays re- Spatial and temporal regulation of 3-phosphoinositides by PI
duced sensitivity to the inhibitor wortmannin. Biochem. J. 326, 3-kinase and PTEN mediates chemotaxis. Cell 109, 611–623.
139–147. 30. Sasaki, T., Irie-Sasaki, J., Jones, R.G., Oliveira-dos-Santos, A.J.,
10. Gaidarov, I., Smith, M.E.K., Domin, J., and Keen, J.H. (2001). Stanford, W.L., Bolon, B., Wakeham, A., Itie, A., Bouchard, D.,
Kozieradzki, I., et al. (2000). Function of PI3K in thymocyteThe class II phosphoinositide 3-kinase C2- is activated by
Review
213
development, T cell activation and neutrophil migration. Science tidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res. 15,
1135–1139.287, 1040–1044.
31. Hirsch, E., Katanaev, V.L., Garlanda, C., Azzolino, O., Pirola, L., 51. Hosoi, Y., Miyachi, H., Matsumoto, Y., Ikehata, H., Komura, J.,
Ishii, K., Zhao, H.J., Yoshida, M., Takai, Y., Yamada, S., et al.Silengo, L., Sozzani, S., Mantovani, A., Altruda, F., and Wymann,
M. (2000). Central role for G protein-coupled phosphoinostide (1998). A phosphatidylinositol 3-kinase inhibitor wortmannin in-
duces radioresistant DNA synthesis and sensitizes cells to bleo-3-kinase- in inflammation. Science 287, 1049–1053.
32. Li, Z., Jiang, H., Zie, W., Zhang, Z., Smrcka, A.V., and Wu, D. mycin and ionizing radiation. Int. J. Cancer 78, 642–647.
52. Edwards, E., Geng, L., Tan, J., Onishko, H., Donnelly, E., and(2000). Roles of PLC-2 and -3 and PI3K in chemoattractant-
mediated signal transduction. Science 287, 1046–1049. Hallahan, D.E. (2002). Phosphatidylinositol 3-kinase/Akt signal-
ling in the response of vascular endothelium to ionizing radia-33. Helgason, C.D., Damen, J.E., Rosten, P., Grewal, R., Sorensen,
P., Chappel, S.M., Borowski, A., Jirik, F., and Humphries, R.K. tion. Cancer Res. 62, 4671–4677.
53. Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan,(1998). Targeted disruption of SHIP leads to hemopoietic pertur-
bations in lung pathology, and a shortened life span. Genes M.E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S.N., et
al. (2001). Involvement of chemokine receptors in breast cancerDev. 12, 1610–1620.
34. Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., metastasis. Nature 410, 50–56.
Peskett, E., Pearce, W., Meek, S.E., Salpekar, A., Waterfield, 54. Shioi, T., Kang, P.M., Douglas, P.M., Hampe, J., Yballe, C.M.,
M.D., et al. (2002). Impaired B and T cell antigen receptor in Lawitts, J., Cantley, L.C., and Izumo, S. (2000). The conserved
p110 PI 3-kinase mutant mice. Science 297, 1031–1034. phosphoinositide 3-kinase pathway determines heart size in
35. Laffargue, M., Calvez, R., Finan, P., Trifilieff, A., Barbier, M., mice. EMBO J. 19, 2537–2548.
Altruda, F., Hirsch, E., and Wymann, M.P. (2002). Phosphoinosi- 55. Shioi, T., McMullen, J.R., Kang, P.M., Douglas, P.S., Obata, T.,
tide 3-kinase- is an essential amplifier of mast cell function. Franke, T.F., Cantley, L.C., and Izumo, S. (2002). Akt/protein
Immunity 16, 441–451. kinase B promotes organ growth in transgenic mice. Mol. Cell.
36. Rittenhouse, S.E. (1996). Phosphoinositide 3-kinase and platelet Biol. 22, 2799–2809.
function. Blood 88, 4401–4414. 56. Matsui, T., Li, L., Wu, J.C., Cook, S.A., Nagoshi, T., Picard,
37. Hirsch, E., Bosco, O., Tropel, P., Laffargue, M., Calvez, R., Al- M.H., Liao, R., and Rosenzweig, A. (2002). Phenotypic spectrum
truda, F., Wymann, M.P., and Montruchhio, G. (2001). Resis- caused by transgenic overexpression of activated Akt in the
tance to thromboembolism in PI3K-deficient mice. FASEB J. heart. J. Biol. Chem. 277, 22896–22901.
15, 2019–2022. 57. Matsui, T., Tao, J., del Monte, F., Lee, K.H., Li, L., Picard, M.,
38. Crackower, M.A., Oudit, G.Y., Kozieradzki, I., Sarao, R., Hirsch, Force, T.L., Franke, T.F., Hajjar, R.J., and Rosenzweig, A. (2001).
E., Suzuki, A., Shioi, T., Irie-Sasaki, J., Sah, R., Cheng, H.Y.M., Akt activation preserves cardiac function and prevents injury
et al. (2002). Regulation of myocardial contractility and cell size after transient cardiac ischemia in vivo. Circulation 104, 330–
by distinct PI3K-PTEN pathways. Cell 10, 737–749. 335.
39. Northcott, C.A., Poy, M.N., Najjar, S.M., and Watts, S.W. (2002). 58. Fujio, Y., Nguyen, T., Wencker, D., Kitsis, R.N., and Walsh, K.
Phosphoinositide 3-kinase mediates enhanced spontaneous (2001). Akt promotes survival of cardiomyocytes in vitro and
and agonist-induced contraction in aorta of deoxycorticoster- protects against ischemia-reperfusion injury in mouse heart.
one acetate–salt hypertensive rats. Circ. Res. 91, 360–369. Circulation 101, 660–667.
40. Sata, M., and Nagai, R. (2002). Phosphatidylinositol 3-kinase: a
key regulator of vascular tone. Circ. Res. 91, 273–275. Note Added in Proof
41. Shayesteh, L., Lu, Y.L., Kuo, W.L., Baldocchi, R., Godfrey, T.,
Collins, C., Pinkel, D., Powell, B., Mills, G.B., and Gray, J.W. Another quinazolinone-related compound, IC87114, has been re-
(1999). PIK3CA is implicated as an oncogene in ovarian cancer. ported recently by ICOS to have an IC50 for p110 of 0.5M, whereas
Nat. Genet. 21, 99–102. IC50 values for p110, p110, and PI3K were 100, 75, and 29 M,
42. Ma, Y.Y., Wei, S.J., Lin, Y.C., Lung, J.C., Chang, T.C., Whang- respectively: Sadhu, C., Masinovsky, B., Dick, K., Sowell, C.G., and
Peng, J., Liu, J.M., Yang, D.M., Yang, W.K., and Schen, C.Y. Staunton, D.E. (2003). Essential role of phosphoinositide 3-kinase
(2000). PIK3CA as an oncogene in cervical cancer. Oncogene delta in neutrophil directional movement. J. Immunol. 170,
19, 2739–2744. 2647–2654.
43. Simpson, L., and Parsons, R. (2002). PTEN: Life as a tumor
suppressor. Exp. Cell Res. 264, 29–41.
44. Testa, J.R., and Bellacosa, A. (2002). AKT plays a central role
in tumorigenesis. Proc. Natl. Acad. Sci. USA 98, 10983–10985.
45. Liang, J., Zubovitz, J., Petrocelli, T., Kotchetkov, R., Connor,
M.K., Han, K., Lee, J.H., Ciarallo, S., Catzavelos, C., Beniston,
R., et al. (2002). PKB/Akt phosphorylates p27, impairs nuclear
import of p27 and opposes p27-mediated G1 arrest. Nat. Med.
8, 1153–1160.
46. Shin, I., Yakes, F.M., Rojo, F., Shin, N.Y., Bakin, A.V., Baselga,
J., and Arteaga, C.L. (2002). PKB/Akt mediates cell-cycle pro-
gression by phosphorylation of p27(Kip1) at threonine 157 and
modulation of its cellular localization. Nat. Med. 8, 1145–1152.
47. Viglietto, G., Motti, M.L., Bruni, P., Melillo, R.M., D’Alessio, A.,
Califano, D., Vinci, F., Chiappetta, G., Tsichlis, P., Bellacosa, A.,
et al. (2002). Cytoplasmic relocalization and inhibition of the
cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-medi-
ated phosphorylation in breast cancer. Nat. Med. 8, 1136–1144.
48. Mayo, L.D., and Donner, D.B. (2002). The PTEN, Mdm2, p53
tumor suppressor-oncoprotein network. Trends Biochem. Sci.
27, 462–467.
49. Hu, L.M., Hofmann, J., Lu, Y.L., Mills, G.B., and Jaffe, R.B. (2000).
Inhibition of phosphatidylinositol 3-kinase increases efficacy of
paclitaxel in in vitro and in vivo ovarian cancer models. Cancer
Res. 62, 1087–1092.
50. Schultz, R.M., Merriman, R.L., Andis, S.L., Bonjouklian, R., Grin-
dey, G.B., Rutherford, P.G., Gallegos, A., Massey, L., and Powis,
G. (1995). In-vitro and in-vivo anti-tumor activity of the phospha-
